From GlobeNewswire: 2025-04-25 20:06:00

Skye Bioscience, Inc. (Nasdaq: SKYE) granted a non-qualified stock option award to purchase 19,000 shares of its common stock to a new non-executive employee under the 2024 Inducement Equity Incentive Plan. The stock options have an exercise price of $1.73 per share and will vest over four years. Skye is focused on developing next-generation molecules for metabolic health and is conducting a Phase 2 clinical trial in obesity for nimacimab, a negative allosteric modulating antibody. For more information, visit their website. Contact Skye Bioscience for investor relations or media inquiries. This press release contains forward-looking statements.



Read more at GlobeNewswire: Skye Announces Inducement Grant Under Nasdaq Listing Rule